

**E-SE- sodium selenite and .alpha.-tocopherol acetate, d- injection, solution**  
**Schering Corporation**

-----  
**E-SE®**  
**(SELENIUM, VITAMIN E)**  
**Injection**

FOR VETERINARY USE ONLY

Approved by FDA under NADA # 030-315

**PRODUCT INFORMATION**

**CAUTION** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION** E-SE Injection is an emulsion of selenium-tocopherol for the prevention and treatment of myositis (Selenium-Tocopherol Deficiency) syndrome in horses. **Each mL contains:** 5.48 mg sodium selenite (equivalent to 2.5 mg selenium), 50 mg (68 USP units or IU) vitamin E (as *d*-alpha tocopheryl acetate), 250 mg polyoxyethylated vegetable oil, 2% benzyl alcohol (preservative), water for injection q.s. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH.

**PHARMACOLOGY** It has been demonstrated that selenium and tocopherol exert physiological effects and that these effects are intertwined with sulfur metabolism. Additionally, tocopherol appears to have a significant role in the oxidation process, thus suggesting an interrelationship between selenium and tocopherol in overcoming sulfur-induced depletion and restoring normal metabolism. Although oral ingestion of adequate amounts of selenium and tocopherol would seemingly restore normal metabolism, it is apparent that the presence of sulfur and, perhaps, other factors interfere during the digestive process with proper utilization of selenium and tocopherol. When selenium and tocopherol are injected, they bypass the digestive process and exert their full metabolic effects promptly on cell metabolism. Anti-inflammatory action has been demonstrated by selenium-tocopherol in the Selye Pouch Technique and experimentally induced polyarthritis study in rats.

**INDICATIONS** E-SE Injection is recommended for the control of the following clinical signs when associated with myositis (Selenium-Tocopherol Deficiency) syndrome: rapid respiration, profuse sweating, muscle spasms and stiffness, elevated SGOT.

**CAUTION** Intravenous administration, if elected, should be by slow injection.

Emulsions injected intramuscularly into the horse may produce transitory local muscle soreness and can be prevented to some degree by injecting deeply (2 to 2 1/2 inches), in divided doses, in two or more sites. Do not continue therapy in horses demonstrating such sensitivity.

Selenium is toxic if administered in excess. A fixed dose schedule is therefore important (read package insert for each selenium-tocopherol product carefully before using).

**WARNINGS** Anaphylactoid reactions, some of which have been fatal, have been reported in horses administered E-SE Injection. Signs include excitement, sweating, trembling, ataxia, respiratory distress, and cardiac dysfunction. These reactions have been reported as associated both with intravenous and intramuscular injections. It is

presently unknown whether the mode of application affects the frequency of such reactions. However, reactions associated with intramuscular injections have been reported to manifest more slowly and hence may give more time to institute treatment for anaphylaxis, such as epinephrine and/or corticosteroid injection.

Medications which have been reported to cause major adverse reactions in horses should be avoided when E-SE is administered, unless the condition of the animal requires such use.

Not to be used in horses intended for food.

**DOSAGE AND ADMINISTRATION** *Administration:* slow intravenous injection (see **WARNINGS**) or deep intramuscular injections, in divided doses, in two or more sites in the gluteal or cervical muscles. *Dosage:* 1 mL per 100 pounds of body weight. May be repeated at 5-10 day intervals.

**PRECAUTIONS** Selenium-Tocopherol Deficiency (STD) syndrome produces a variety and complexity of symptoms often interfering with a proper diagnosis. Even in selenium deficient areas there are other disease conditions which produce similar clinical signs. It is imperative that all these conditions be carefully considered prior to treatment of STD syndrome. Serum selenium levels, elevated SGOT, and creatine levels may serve as aids in arriving at a diagnosis of STD, when associated with other indices.

**Important** Use only the selenium-tocopherol product recommended for each species. Each formulation is designed for the species indicated to produce the maximum efficacy and safety.

**HOW SUPPLIED** 100 mL sterile, multiple-dose glass vial, NDC 0061-0709-04.

**STORAGE** Store between 2 and 30 C (36 and 86 F). Protect from freezing.

Rev. 10-2022

Copyright © 2022 Merck & Co., Inc., Rahway,  
NJ, USA and its affiliates.  
All rights reserved.  
Made in Germany.

MERCK  
Animal Health  
399371 R2

**PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton**

100 mL Sterile  
Multiple Dose Vial  
2.5 mg/mL

SELENIUM

NDC 0061-0709-04

E-SE®  
(SELENIUM, VITAMIN E)

Injection

Veterinary

Caution: Federal law restricts  
this drug to use by or on the  
order of a licensed veterinarian.

Approved by FDA under  
NADA # 030-315

MERCK  
Animal Health



## E-SE

sodium selenite and .alpha.-tocopherol acetate, d- injection, solution

### Product Information

<b>Product Type</b>	PRESCRIPTION ANIMAL DRUG	<b>Item Code (Source)</b>	NDC:0061-0709
<b>Route of Administration</b>	INTRAVENOUS, INTRAMUSCULAR		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>SODIUM SELENITE</b> (UNII: HIW548RQ3W) (SELENITE ION - UNII:KXO0259XJ1)	SELENIUM	2.5 mg in 1 mL
<b>.ALPHA.-TOCOPHEROL ACETATE, D-</b> (UNII: A7E6112E4N) (.ALPHA.-TOCOPHEROL, D- - UNII:N9PR3490H9)	.ALPHA.-TOCOPHEROL, D-	68 [USP'U] in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
<b>WATER</b> (UNII: 059QF0KO0R)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0061-0709-04	1 in 1 CARTON		
1		100 mL in 1 VIAL, MULTI-DOSE		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA030315	07/09/1964	

**Labeler** - Schering Corporation (001317601)

Revised: 11/2024

Schering Corporation